Investment by Major Companies Propelled Somatostatinoma Treatment Market
Somatostatinoma is an extremely rare pancreatic neuroendocrine tumor (PNET) or duodenal endocrine tumor (DNET), which originates either in the pancreas (50%) or the gastrointestinal tract (50%)
Based on data published in the National Center for Biotechnology Information, an estimated incidence rate of Somatostatinoma is of 1/40,000,000 globally.
Companies are investing in research to develop innovative and effective treatment procedures. For instance, In June 2018, Boehringer Ingelheim announced to invest US$ 270 Mn to build a new Biologicals Development Center (BDC) specialized for immunology and immune-oncology. The initiatives like these are expected to fuel the market growth during the forecast period.
Request a Brochure of Somatostatinoma Treatment Market Report –
Key Drivers and Restraints of Global Somatostatinoma Treatment Market
The adoption rate of drugs for treatment of Somatostatinoma rises with increase in prevalence of the disease. Majority, that is three-quarters (78%), of somatostatinomas are malignant and the great majority of these (70%–92%) is present with metastatic disease.
Ongoing research activities throughout the world propel the market. Ga labeled radionucleotide therapies and radiofrequency ablation technique, are the major factors driving the demand for somatostatinoma treatment.
The major restraining factor of the somatostatinoma treatment market is high cost of treatment. The treatment of somatostatinoma is not available in every hospital; moreover, it is very expensive.
Combination Drug Therapy to Witness High Demand
Based on treatment type, the global somatostatinoma treatment market can be segmented into combination drug therapy, surgical, radiofrequency ablation (RFA), transarterial embolization, and others
Combination drug therapy accounted for highest market share in 2018. The treatment usually consists of combination of intravenous 5-fluorouracil (5-FU) and streptozotocin drugs. However, Doxorubicin and 5-FU have also been used and may be a more effective combination for the treatment of somatostatinoma.
For More Actionable Insights into The Competitive Landscape of Somatostatinoma Treatment Market , Pre Book This Report –
Specialty Clinics Segment to Witness Highest Growth
Based on end-user, the global somatostatinoma treatment market can be divided into: hospitals, specialty clinics, and cancer & radiation therapy centers
In terms of revenue, hospitals dominated the market in 2018, due to large number of procedures performed in these facilities
The specialty clinics segment is anticipated to grow with the highest CAGR during the forecast period. This can be attributed to the presence of developed technologies and availability of multiple options for somatostatinoma diagnosis and treatments.
Various market players are also collaborating with medical institutions and research centers to provide educational services to health care professionals to help them enhance their skills
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Transparency Market Research
90 State Street,
Albany NY – 12207
USA – Canada Toll Free: 866-552-3453
Email: [email protected]